CRB-913 in Obesity
Corbus is sharing topline data from CANYON-1, a Phase 1b study evaluating CRB-913 in 240 adults with obesity and without diabetes. CRB-913 is a once-daily, highly peripherally restricted oral CB1 inverse agonist being developed as a potential non-incretin approach to weight loss and long-term weight management.
Explore the latest CANYON-1 updates, including our topline data webcast, external perspectives, upcoming scientific presentations and related events.
Upcoming
Presentations and Events
CRB-913 at Obesity Week 2026
CANYON-1 data have been selected for a late-breaking presentation at ObesityWeek 2026, taking place November 14–17 in Washington, DC.
Featured Coverage and Interviews
Explore recent coverage and conversations about CANYON-1, CRB-913 and the evolving treatment landscape in obesity.
Ahead of CANYON-1: CRB-913 and its potential in obesity
Ahead of the CANYON-1 topline data readout, Corbus CEO Yuval Cohen discussed CRB-913 and its potential in obesity on the Molecules and Minerals podcast.